Therefore, we speculate that higher PD-L1 expression in NSCLC patients may lead to EGFR-TKI resistance through tumor microenvironment and eventually result in a poor prognosis for TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.